BSA-based dosing and alternative approaches

Clinical Advances in Hematology and Oncology

Volumn 3, Issue 6, 2005, Pages 448-450

  Sparreboom, Alex ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CYTOTOXIC AGENT; ERLOTINIB; FLUOROURACIL; MERCAPTOPURINE; METHOTREXATE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BASAL METABOLIC RATE; BLOOD VOLUME; BODY SURFACE; BONE MARROW TOXICITY; CANCER; DOSE CALCULATION; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG METABOLISM; GENE TARGETING; GLOMERULUS FILTRATION RATE; HUMAN; NONHUMAN; OBESITY; SIDE EFFECT;

ANTINEOPLASTIC AGENTS; BODY SURFACE AREA; HUMANS; NEOPLASMS;

EID: 26044464800     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Baker SD, Verweij J, Rowinsky EK, et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst. 2002;94:1883-1888.
2. Duffull SB, Dooley MJ, Green B, Poole SG, Kirkpatrick CM. A standard weight descriptor for dose adjustment in the obese patient. Clin Pharmacakinet. 2004;43:1167-1178.
3. Felici A, Verweij J, Sparreboom A. Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer. 2002;38:1677-1684.
4. Gurney H. How to calculate the dose of chemotherapy. Br J Cancer.2002;86:1297-1302.
5. Sawyer M, Ratain MJ. Body-surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs. 2001;19:171-177.